Adverse events and tolerability of combined durvalumab and tremelimumab versus durvalumab alone in solid cancers: a systematic review and meta-analysis

• Main Authors: Fahmy, Omar, Ahmed, Osama A. A., Khairul-Asri, Mohd Ghani, Alhakamy, Nabil A., Alharbi, Waleed S., Fahmy, Usama A., El-Moselhy, Mohamed A., Fresta, Claudia G., Caruso, Giuseppe, Caraci, Filippo
• Format: Article
• Published: Multidisciplinary Digital Publishing Institute 2022
• Online Access: http://psasir.upm.edu.my/id/eprint/100141/; https://www.mdpi.com/2227-9059/10/5/1101
• Institution: Universiti Putra Malaysia

Background: Recently, the combination of durvalumab and tremelimumab, two immune checkpoint inhibitors, for the treatment of different types of cancers has been considered; however, its overall effects, including its safety, are still unclear and need to be further investigated. Objectives: The aim...